Colon cancer, version 3.2014

Al B. Benson; Alan P. Venook; Tanios Bekaii-Saab; Emily Chan; Yi Jen Chen; Harry S. Cooper; Paul F. Engstrom; Peter C. Enzinger; Moon J. Fenton; Charles S. Fuchs; Jean L. Grem; Steven Hunt; Ahmed Kamel; Lucille A. Leong; Edward Lin; Wells Messersmith; Mary F. Mulcahy; James D. Murphy; Steven Nurkin; Eric Rohren; David P. Ryan; Leonard Saltz; Sunil Sharma; David Shibata; John M. Skibber; Constantinos T. Sofocleous; Elena M. Stoffel; Eden Stotsky-Himelfarb; Christopher G. Willett; Kristina M. Gregory; Deborah A. Freedman-Cass

doi:10.6004/jnccn.2014.0099

Colon cancer, version 3.2014

Al B. Benson, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Wells Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric RohrenDavid P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, Deborah A. Freedman-Cass

Nuclear Medicine

Research output: Contribution to journal › Article › peer-review

198 Scopus citations

Abstract

The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.

Original language	English (US)
Pages (from-to)	1028-1059
Number of pages	32
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	12
Issue number	7
DOIs	https://doi.org/10.6004/jnccn.2014.0099
State	Published - Jul 1 2014

ASJC Scopus subject areas

Oncology

Access to Document

10.6004/jnccn.2014.0099

Cite this

Benson, A. B., Venook, A. P., Bekaii-Saab, T., Chan, E., Chen, Y. J., Cooper, H. S., Engstrom, P. F., Enzinger, P. C., Fenton, M. J., Fuchs, C. S., Grem, J. L., Hunt, S., Kamel, A., Leong, L. A., Lin, E., Messersmith, W., Mulcahy, M. F., Murphy, J. D., Nurkin, S., ... Freedman-Cass, D. A. (2014). Colon cancer, version 3.2014. JNCCN Journal of the National Comprehensive Cancer Network, 12(7), 1028-1059. https://doi.org/10.6004/jnccn.2014.0099

Benson, AB, Venook, AP, Bekaii-Saab, T, Chan, E, Chen, YJ, Cooper, HS, Engstrom, PF, Enzinger, PC, Fenton, MJ, Fuchs, CS, Grem, JL, Hunt, S, Kamel, A, Leong, LA, Lin, E, Messersmith, W, Mulcahy, MF, Murphy, JD, Nurkin, S, Rohren, E, Ryan, DP, Saltz, L, Sharma, S, Shibata, D, Skibber, JM, Sofocleous, CT, Stoffel, EM, Stotsky-Himelfarb, E, Willett, CG, Gregory, KM & Freedman-Cass, DA 2014, 'Colon cancer, version 3.2014', JNCCN Journal of the National Comprehensive Cancer Network, vol. 12, no. 7, pp. 1028-1059. https://doi.org/10.6004/jnccn.2014.0099

@article{6d77323a9d11434ca4b40beb47b5c089,

title = "Colon cancer, version 3.2014",

abstract = "The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.",

author = "Benson, {Al B.} and Venook, {Alan P.} and Tanios Bekaii-Saab and Emily Chan and Chen, {Yi Jen} and Cooper, {Harry S.} and Engstrom, {Paul F.} and Enzinger, {Peter C.} and Fenton, {Moon J.} and Fuchs, {Charles S.} and Grem, {Jean L.} and Steven Hunt and Ahmed Kamel and Leong, {Lucille A.} and Edward Lin and Wells Messersmith and Mulcahy, {Mary F.} and Murphy, {James D.} and Steven Nurkin and Eric Rohren and Ryan, {David P.} and Leonard Saltz and Sunil Sharma and David Shibata and Skibber, {John M.} and Sofocleous, {Constantinos T.} and Stoffel, {Elena M.} and Eden Stotsky-Himelfarb and Willett, {Christopher G.} and Gregory, {Kristina M.} and Freedman-Cass, {Deborah A.}",

year = "2014",

month = jul,

day = "1",

doi = "10.6004/jnccn.2014.0099",

language = "English (US)",

volume = "12",

pages = "1028--1059",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

publisher = "Cold Spring Publishing LLC",

number = "7",

}

TY - JOUR

T1 - Colon cancer, version 3.2014

AU - Benson, Al B.

AU - Venook, Alan P.

AU - Bekaii-Saab, Tanios

AU - Chan, Emily

AU - Chen, Yi Jen

AU - Cooper, Harry S.

AU - Engstrom, Paul F.

AU - Enzinger, Peter C.

AU - Fenton, Moon J.

AU - Fuchs, Charles S.

AU - Grem, Jean L.

AU - Hunt, Steven

AU - Kamel, Ahmed

AU - Leong, Lucille A.

AU - Lin, Edward

AU - Messersmith, Wells

AU - Mulcahy, Mary F.

AU - Murphy, James D.

AU - Nurkin, Steven

AU - Rohren, Eric

AU - Ryan, David P.

AU - Saltz, Leonard

AU - Sharma, Sunil

AU - Shibata, David

AU - Skibber, John M.

AU - Sofocleous, Constantinos T.

AU - Stoffel, Elena M.

AU - Stotsky-Himelfarb, Eden

AU - Willett, Christopher G.

AU - Gregory, Kristina M.

AU - Freedman-Cass, Deborah A.

PY - 2014/7/1

Y1 - 2014/7/1

N2 - The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.

AB - The NCCN Guidelines for Colon Cancer address diagnosis, pathologic staging, surgical management, perioperative treatment, posttreatment surveillance, management of recurrent and metastatic disease,and survivorship. This portion of the guidelines focuses on the use of systemic therapy in metastatic disease. The management of metastatic colorectal cancer involves a continuum of care in which patients are exposed sequentially to a variety of active agents, either in combinations or as single agents. Choice of therapy is based on the goals of treatment, the type and timing of prior therapy, the different efficacy and toxicity profiles of the drugs, the mutational status of the tumor, and patient preference.

UR - http://www.scopus.com/inward/record.url?scp=84903980978&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903980978&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2014.0099

DO - 10.6004/jnccn.2014.0099

M3 - Article

C2 - 24994923

AN - SCOPUS:84903980978

SN - 1540-1405

VL - 12

SP - 1028

EP - 1059

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 7

ER -

Colon cancer, version 3.2014

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this